Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 2, 2005, Pages 578-585

  Rojas, Jeannie R ^a   Taylor, Ronald P ^b   Cunningham, Mark R ^c   Rutkoski, Thomas J ^a   Vennarini, Joseph ^a   Jang, Haishan ^a   Graham, Martin A ^a   Geboes, Karel ^d   Rousselle, Serge D ^c   Wagner, Carrie L ^a  

^a CENTOCOR INC   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c CHARLES RIVER LABORATORIES   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROHN DISEASE; DRUG MECHANISM; EXPERIMENTAL MODEL; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOGENICITY; MONKEY; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; BLOOD CHEMICAL ANALYSIS; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; GAMMA CAMERAS; HEMATOLOGIC TESTS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; ORGAN SPECIFICITY; RECEPTORS, COMPLEMENT 3B;

EID: 20944434562     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.079277     Document Type: Article

References (20)

1. Aderem A and Underhill DM (1999) Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 17:593-623.
2. Ahmed SS, Muro H, Nishimura M, Kosugi I, Tsutsui Y, and Shirasawa H (1995) Fc receptors in liver sinusoidal endothelial cells in NZB/W F1 lupus mice: a histological analysis using soluble immunoglobulin G-immune complexes and a monoclonal antibody (2.4G2) (1995) Hepatology 22:316-324.
3. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, and Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:601-608.
4. Cornacoff JB, Hebert LA, Smead WL, and Vanaman ME (1983) Primate erythrocyte-immune complex-clearing mechanism. J Clin Investig 71:236-247.
5. Daëron M (1997) Fc receptor biology. Annu Rev Immunol 15:203-234.
6. Davies KA, Mathieson P, Winearls CG, Rees AJ, and Walport MJ (1990) Serum sickness and acute renal failure after streptokinase therapy for myocardial infarction. Clin Exp Immunol 80:83-88.
7. Davies KA, Robson MG, Peters AM, Norsworthy P, Nash JT, and Walport MJ (2002) Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus. Arthritis Rheum 46:1028-1038.
8. Ferguson PJ, Reist CJ, Martin EN, Johnson C, Greene KL, Kuhn S, Niebur J, Emlen W, and Taylor RP (1995) Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis Rheum 38:190-200.
9. Fraker PJ and Speck JC Jr (1978) Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a- diphrenylglycoluril. Biochem Biophys Res Commun 80:849-857.
10. Guide for the Care and Use of Laboratory Animals (1996). Institute of Laboratory Animal Resources Commission on Life Sciences; National Research Council. National Academy Press, Washington, D.C.
11. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, and Rutgeerts P (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2:542-553.
12. Hespeling U, Jungermann K, and Puschel GP (1995) Feedback-inhibition of glucagon-stimulated glycogenolysis in hepatocyte/Kupffer cell cocultures by glucagon-elicited prostaglandin production in Kupffer cells. Hepatology 22:1577-1583.
13. Johansson A, Erlandsson A, Eriksson D, Ullen A, Holm P, Sundstrom BE, Roux KH, and Stigbrand T (2002) Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 94:1306-1313.
14. Lovdal T, Andersen E, Brech A, and Berg T (2000) Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci 113:3255-3266.
15. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor [alpha] monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563.
16. Muro H, Shirasawa H, Kosugi I, and Nakamura S (1993) Defect of Fc receptors and phenotypical changes in sinusoidal endothelial cells in human liver cirrhosis. Am J Pathol 143:105-120.
17. 1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 135:2005-2014.
18. Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720-1740.
19. Schifferli JA and Taylor RP (1989) Physiological and pathological aspects of circulating immune complexes. Kidney Int 35:993-1003.
20. Taylor RP, Sutherland WM, Martin EN, Ferguson PJ, Reinagel ML, Gilbert E, Lopez K, Incardona NL, and Ochs HD (1997) Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J Immunol 158:842-850.